Annovis Bio, Inc. (ANVS) - Dilution Analysis

8-K filing: Annovis Bio, Inc. entered into an underwriting agreement to issue and sell 7,895,000 shares of common stock and warrants to purchase 7,105,500 shares in a public offering with expected gross proceeds of approximately $15 million. ($15.0M proceeds)

10-Q filing | 27.8M shares outstanding

10-Q filing | 19.7M shares outstanding

8-K filing: Annovis Bio, Inc. entered into a Securities Purchase Agreement and Stock Subscription Agreements to issue and sell 1,670,732 shares of common stock at $2.05 per share in a registered direct offering, expected to close on October 28, 2025, with gross proceeds of approximately $3.425 million. ($3.43M proceeds)

10-Q filing | 19.5M shares outstanding

10-Q filing | 19.5M shares outstanding

10-K filing | 14.1M shares outstanding

8-K filing: Annovis Bio, Inc. completed an underwritten public offering of 5,250,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, at a per unit price of $4.00, for aggregate gross proceeds of $21,000,000. ($21.0M proceeds)

10-Q filing | 13.0M shares outstanding

10-Q filing | 11.3M shares outstanding

10-Q filing | 10.8M shares outstanding

8-K filing: Annovis Bio, Inc. entered into a Common Stock Purchase Agreement with an Equity Line investor, potentially offering and selling up to 2,051,428 shares of common stock at the Company's discretion. ($0.38M proceeds)

10-K filing | 10.5M shares outstanding

8-K filing: Annovis Bio, Inc. closed an offering on March 22, 2024, issuing 316,455 shares of common stock at $9.48 per share, raising $3,000,000 in gross proceeds. ($3.0M proceeds)

8-K filing: Annovis Bio, Inc. entered into a Securities Purchase Agreement to issue and sell 316,455 shares of Common Stock at $9.48 per share for aggregate gross proceeds of $3,000,000 to an institutional investor. ($3.0M proceeds)

8-K filing: Annovis Bio, Inc. closed an offering of 114,911 shares of Common Stock at $8.92 per share on March 19, 2024, raising $1,025,000 in gross proceeds. ($1.03M proceeds)

8-K filing: Annovis Bio, Inc. entered into a Securities Purchase Agreement to issue and sell 114,911 shares of Common Stock at $8.92 per share for aggregate gross proceeds of $1,025,000 to an institutional investor. ($1.03M proceeds)

S-3/A filing: This is an S-3/A filing for Annovis Bio, Inc., indicating a shelf registration for common stock to be offered on a delayed or continuous basis pursuant to Rule 415.

S-3 filing: Annovis Bio, Inc. may offer and sell shares of common stock, shares of preferred stock, debt securities, warrants, or any combination of those securities, either individually or in units, up to an aggregate initial offering price of $250,000,000.

10-Q filing | 9.0M shares outstanding

8-K filing: Annovis Bio, Inc. entered into an underwriting agreement with Cannacord Genuity LLC for a public offering of 1,250,000 shares of common stock and warrants to purchase 1,250,000 shares, priced at $6.00 per unit, expected to close on or about November 2, 2023. ($7.5M proceeds)

10-Q filing | 9.0M shares outstanding

10-Q filing | 8.2M shares outstanding

8-K filing: The Company sold 704,000 Shares pursuant to the Sales Agreement at a price of $10.88 per Share, for gross proceeds of $7,659,520 before commissions and terminated the Sales Agreement, ceasing further offerings. ($7.66M proceeds)

10-K filing | 8.2M shares outstanding

10-Q filing | 8.2M shares outstanding

10-Q filing | 8.2M shares outstanding

10-Q filing | 8.2M shares outstanding

10-K filing | 7.6M shares outstanding

10-Q filing | 6.9M shares outstanding

10-Q filing | 6.9M shares outstanding

8-K filing: Annovis Bio, Inc. entered into an underwriting agreement with ThinkEquity for a public offering of 1,000,000 shares of common stock at $50.00 per share. ($50.0M proceeds)

10-Q filing | 6.9M shares outstanding

10-K filing | 6.9M shares outstanding

S-3 filing: The filing is an S-3 registration statement for a shelf offering of common stock, preferred stock, warrants, or units, or any combination of those securities, up to an aggregate initial offering price of $250,000,000.

10-Q filing | 6.9M shares outstanding

10-Q filing | 6.9M shares outstanding

10-Q filing | 6.9M shares outstanding

S-1/A filing: This S-1/A filing relates to the registration of Firm Shares, an over-allotment option, and representative's warrants for common stock.

S-1/A filing: This S-1/A filing registers common stock offered through ThinkEquity, including firm shares and an over-allotment option, as well as representative's warrants, to advance preclinical and clinical development of ANVS-401 and for general corporate purposes.